Brepocitinib

Phase 3Small molecule

PPriovant Therapeutics, Inc.

Brepocitinib is one of 9 small molecule programs targeting Anterior Uveitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anterior UveitisActive, not recruiting

Anterior UveitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Anterior Uveitis

#DrugCompanyPhaseTrials

Rinvoq

AbbVie

Approved

1 2

Cimzia

UCB

Approved

—3

Rapamune

PPrism Pharmaceuticals

Approved

—4

Decadron

AAspen Global Incorporated

Approved

—5

Tobrex

VViatris Specialty LLC

Olumiant

1 7

Brepocitinib

PPriovant Therapeutics, Inc.

Phase 3

2 8

Cytovene

EExela Pharma Sciences, LLC.

Preclinical

1 9

Lotemax

PPharmos

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Anterior Uveitis

NCT06431373

Q4 2029

PreclinicalRecruiting

Sarcoidosis

NCT06978725

Clinical

Trials by Indication[1]

Anterior Uveitis2 trials

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

Completed·PPriovant Therapeutics, Inc.·Phase 2·NCT05523765·26 enrolled

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Active, not recruiting·PPriovant Therapeutics, Inc.·Phase 3·NCT06431373·371 enrolled

Dermatomyositis2 trials

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Completed·PPriovant Therapeutics, Inc.·Phase 2·NCT06433999·5 enrolled

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis

Completed·PPriovant Therapeutics, Inc.·Phase 3·NCT05437263·241 enrolled

Sarcoidosis1 trial

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

Recruiting·PPriovant Therapeutics, Inc.·Preclinical·NCT06978725·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Brepocitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brepocitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brepocitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Priovant Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPriovant Therapeutics, Inc.

Brepocitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2029

Trials by Indication[1]

Anterior Uveitis2 trials

Dermatomyositis2 trials

Sarcoidosis1 trial

References

Drug Info

Quick Facts

Related News